How Capitalism Makes Things Better… and Cheaper

Shield

AN OXFORD CLUB PUBLICATION

Loyal reader since August 2025 

View in browser

SPONSORED

Stop chasing NVIDIA

If you’re chasing Nvidia, Amazon, or Palantir right now, I’ve got one word for you: Stop. Because according to legendary investor Whitney Tilson, AI mania is about to leave millions of investors holding the bag.

Whitney just went public with one of his most controversial predictions in years:

“The AI boom is real… but the next wave of gains won’t come from where everyone expects.”

Instead, he believes a stealthy, little-known stock is about to blow past Nvidia in a way few investors see coming.

Learn the craziest part here…

THE SHORTEST WAY TO A RICH LIFE

How Capitalism Makes Things Better… and Cheaper

Alexander Green, Chief Investment Strategist, The Oxford Club

Many investors earn lower returns than they should because they are far too pessimistic about the future.

That may sound surprising to those who read Monday’s column, where I detailed how government policies make things like houses, cars, groceries, and utilities increasingly unaffordable.

Yet the private sector makes things better and… increasingly affordable.

That sounds like a contradiction. But it’s not.

It is possible for goods to simultaneously become more expensive and more affordable.

To measure affordability, we need to compare the price of goods and services to hourly compensation (wages and benefits).

The resulting ratio is called the time price.

A time price is the length of time the average worker labors to afford something.

Prices are expressed in dollars and cents. But time prices are expressed in hours and minutes.

It’s possible for things to become more expensive in dollars, but cheaper in time.

Which is more meaningful? In our daily lives, time is our most limited and nonrenewable resource.

That’s why time prices matter.

And they reveal something stunning: most things have become dramatically more affordable over time.

Understand this key point: the CPI tells us if something has become more expensive.

But the time price tells us if it has become more affordable.

Time prices are an excellent way to measure increases or decreases in our abundance over time for three reasons:

  • Time prices cannot understate or overstate inflation since prevailing prices and wages are used at every point on the timeline.
  • Time prices are independent of currency fluctuations. (They can be measured in euros, yen, or any other currency.)
  • Time prices provide a standardized way of measuring changes in wellbeing.

In their eye-opening book, Superabundance, authors Marian L. Tupy and Gale L. Pooley measured the costs of 50 commodities between 1980 and 2020.

They didn’t just find that the time prices of some of them went down.

The time prices of all of them went down.

In fact, the average time price decline of those 50 commodities – including oil, natural gas, wheat, cotton, soybeans, beef, corn, pork, and sugar – was a whopping 75.2%.

Put differently, a blue-collar worker had to work 75% less to afford the same amount of these things.

Unless we’re at the gas pump or the grocery store, however, we don’t usually buy commodities. We buy finished goods.

Yet the time price decline in these was just as dramatic. And in many cases, more so.

Over the same 40-year period, the time price of a utensil set declined 51%, a dishwasher declined 62%, a washer declined 65%, men’s clothing declined 72%, a bicycle declined 74%, a vacuum declined 83%, and a food processor declined 86%.

This isn’t cherry-picking. It’s across the board.

And that’s just for blue-collar workers.

White-collar workers – especially those with a college degree – saw time prices drop even more dramatically because their incomes are higher and rose faster.

It’s impossible, of course, to measure the 40-year time price decline in things like laptops, smartphones, and flat-panel TVs because none of these were even imagined in 1980.

SPONSORED

Famous Georgia Trader Reveals #1 Trade On
Monday, December 15

The man who once turned $37k into $2.7 Million in just 4 years and recently closed a 1,129% win after just TWO days on a livestream..

Just revealed the #1 trade to make onMonday, December 15...

All using a strategy that has produced an 81% win-rate over the past year.

See his strategy here.

Other price declines are hard to measure as well.

For example, how do you compare the average cost of a book in 1980 to the more than 10 million that are free to download today from Google’s digital library?

Nobody thinks about the cost of a long-distance phone call today. But growing up, I did.

In college, I could only afford to call from my school in South Carolina to my home in Virginia at night when AT&T offered lower rates.

Today, I routinely have FaceTime calls with friends overseas at no cost.

Over the last 50 years, music listeners have gone from vinyl records to 8-track tapes to cassettes to CDs to MP3 files to streaming.

Today you can listen to almost any song, anywhere, at any time for next to free.

Other products are not free but considerably more affordable when measured in hours worked.

In 1971, a pair of soft contact lenses cost $65, and a fitting by an eye doctor ran about $550, putting the total cost at $615. Unskilled workers earned about $2 an hour.

Today an eye exam is around $120, and lenses start at $200, putting the cost at $320. Unskilled workers earn around $16.51.

In other words, the time price has declined 84%.

In 1970, the price for a roundtrip airline ticket from New York to London was $550.

Blue-collar workers earned $3.93 an hour at the time. (In my family, the folks who spent so lavishly were viewed as members of the “jet set.”)

Today, the same flight has dropped to about $467 and blue-collar workers earn about $36.15. The time price has decreased 91%.

In 1972, you could book a seven-day cruise from Miami to the Caribbean for $240.

Blue-collar workers earned about $4.59 an hour at the time.

Today, you can book a seven-day cruise out of Port Canaveral for $549. For blue-collar workers who earn $36.15 an hour, the price has dropped more than 70%.

Apple introduced the Macintosh in 1984 at a retail price of $2,495.

Unskilled workers earned about $5 an hour at the time.

Today a new iMac sells for $1,299 and unskilled workers earn about $16.51 an hour.

The time price has decreased by 84.2%.

And the difference between a 2025 Mac and the 1984 Mac is like comparing a Lamborghini with a skateboard.

That’s time price abundance.

Not all categories saw time price declines. Healthcare, college tuition, and childcare – heavily regulated, heavily subsidized, and labor-intensive – have outpaced inflation.

These markets don’t benefit from the “economics of knowledge,” where producing multiple copies of a prototype costs less and less.

But even in those areas, alternatives are emerging:

  • Online education is dramatically cheaper and more flexible than traditional degrees.
  • AI in healthcare is improving diagnostics, streamlining care, and lowering costs.
  • Many elective procedures (Lasik, cosmetic surgery, dental implants) have dropped in price significantly – because they’re outside the insurance system and thus more exposed to market forces.

In my new book, I detail how things are likely to become even more affordable in the years ahead, as I’ll discuss in my next column.

Get ready to adjust your investment plan accordingly.

Good investing,

Alex

P.S. Many of you have written to say that my new book is the perfect gift for someone who needs a bit of Christmas cheer. To learn more about The American Dream: Why It’s Still Alive… and How to Achieve Itclick here.Leave a Comment

BUILD AND PROTECT YOUR WEALTH

Donald Trump’s Second Term Could Create 20,000,000 Millionaires

Is Cal-Maine’s 10% Yield About to Go Splat?

Proof: New “One Ticker Payouts” (You Can Do This Weekly!)

From Tariff Hoarding to Chart Collapse: Why Best Buy’s About to Fall 15%

MORE FROM LIBERTY THROUGH WEALTH

Bringing Your Best to Your Future

Why “Boring” Dividend Stocks Build Extraordinary Wealth

Why American Life Has Become Less Affordable

The Most Subversive Book in America

JOIN THE CONVERSATION

FacebookLinkedInEmail Share

SPONSORED

New IPO Stock Creates Massive Controversy Online

After giant Apple deal, some say it will be the next trillion-dollar company. Decide Who’s Right Here.

You are receiving this email because you subscribed to Liberty Through Wealth.
Liberty Through Wealth is published by The Oxford Club.

Questions? Check out our FAQsTrying to reach us? Contact us here.
Please do not reply to this email as it goes to an unmonitored inbox.

Privacy Policy | Whitelist Liberty Through Wealth | Unsubscribe

© 2025 The Oxford Club, LLC All Rights Reserved
The Oxford Club | 105 West Monument Street | Baltimore, MD 21201
North America: 866.237.0436 | International: +1.443.353.4540
Oxfordclub.com

Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation.

Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.

Ref: 000142349377

What’s Happening at NAMI NoVA? Important updates inside

December 2025ABOUT USNEED HELPWAYS TO GIVE

Hold the Line

Our 2025 Annual Campaign

We are halfway through our 2025 Hold the Line annual campaign. To the over 100 people that have contributed so far, THANK YOU!

WHY HOLD THE LINE?

Our community is hurting. “Reduced” out of jobs, fear over Medicaid and other funding cuts, uncertainty if neighbors or themselves might be picked up… and so much more… weighs on us all. In 2025, NAMI Northern Virginia has experienced an almost 65% increase in requests for support, education, and HOPE.

Together, we can meet the needs of our neighbors that need it most. Together, we can hold the line – but to do that, we need your dedication, your sense of purpose, and your support.

For over 48 years, we have relied on the support of our community so we can offer no cost mental health support, education, and advocacy. The need for our life-saving, critical services is greater than ever. 

Hold the Line with us. Help us continue to offer HOPE.

Donate NowHOLD THE LINE WITH US – Donate Now

WEDNESDAY in HERNDON

In Our Own Voice for Youth & Young Adults 

Open and Free for the Public – NAMI Northern Virginia is proud to partner with Floris United Methodist Church for this presentation.

Registration required. If a young person under the age of 16 is attending without a parent or guardian, a permission form found HERE must be completed in advance.

During In Our Own Voice for Youth & Young Adults presentations, young adults with mental health conditions share their powerful personal stories in order to change attitudes, assumptions, and stereotypes. Presentations provide:

  • A first-hand account of what it’s like to live with a mental health condition. Our young adult presenters humanize this misunderstood topic by demonstrating that it’s possible – and common – to live well with a mental illness.
  • A chance to ask the presentersquestions, which allows for a deeper understanding of mental health conditions.
  • The understanding that every person living with a mental illness can hope for a bright future.

In Our Own Voice for Youth & Young Adults is best suited for audiences between the ages of 14-30. 

Registration is required. You will be sent the address in Herndon after registering.REGISTER HEREYOUTH PERMISSION SLIP

Volunteer Appreciation Brunch

Last Saturday, we took time to celebrate our amazing, dedicated volunteers with a year-end brunch.

Both long time volunteers and some of our newly trained and onboarded team members came together in community to celebrate our wins and prepare for the year ahead.

Our thanks to the incredible Zak Sandler for performing part of his autobiographical solo musical, “Inside My Head.”

Congratulations to our volunteer award winners:

Mike – Board of Directors Award

Carol and Joan – Spirit of NAMI Northern Virginia Award

Our volunteers are the lifeline of NAMI NoVA. Thank you for your selfless dedication to helping and offering hope to our community.

First Quarter NAMI Family-to-Family Classes

We are working on the final details of our 1st quarter 2026 education class schedule. We will have THREE NAMI Family-to-Family (F2F) classes in early 2026.

These classes fill up FAST! People on our waitlist will have priority registration, so if you are interested in one of these classes, you are encouraged to sign up on our waitlist now. GET ON THE WAITLIST HERE.

Classes planned in quarter 1 are:

  • In-person in Leesburg – beginning early January 2026
  • In-person in Oakton – beginning late January 2026
  • Virtual – beginning in February

More details coming soon.

Our offices will be closed from Wednesday, December 24 thru Monday, January 5, 2026.We are giving our team a break to spend time with family and focus on their own mental wellness.

We will be monitoring our general email – info@nami-nova.org. Please contact us with any questions or if you need help.

IMPORTANT CALENDAR UPDATES – Many of our support groups have alternate schedules over the next 4 weeks due to the holiday season. Please see our calendar for the most up-to-date schedule.CHECK OUT OUR CALENDAR FOR MOST CURRENT EVENTS SCHEDULE

NAMI Northern Virginia is a 48-year old 501(c)3 nonprofit organization whose mission is to serve Northern Virginia individuals, family members, and friends affected by mental health challenges through awareness, education, support, advocacy, and collaboration with community partners.

NAMI Northern Virginia | Post Office Box 480  |Oakton, VA 22124 US

Unsubscribe | Constant Contact Data Notice

Buy the stock when it touches this ONE line on the chart

In 2008, I went on CNBC and warned of a huge crash in the market. 

They laughed at me on live television…see it here! 



I told readers to get out of stocks in February 2020 before one of the fastest crashes in US history. 

Others still were skeptical. 

You would’ve traded Nvidia, Tesla, Netflix… all the big names and had a shot at making money following me the last few years. 

I’m not guessing when I make these calls. 

All you needed was one, free indicator. 

It’s one I’ve never heard anyone else use, but I’ve traded with it full-time for the last 30 years. 

This indicator alerts me when I should be buying and when to sell. 

You don’t need to be some expert stock trader to use it too… it’s self-explanatory.

My name’s Scott Redler. I’m one of the most well-known traders on Wall Street and I’ll share with you this indicator. 

The indicator is free… and the 23-page book I wrote for you is also free. 

Get the free indicator right here now on the next page.

Scott Redler 
Editor of Power Plays and Co-Founder of T3 Live






Today’s Bonus Content

5 High Short-Interest Stocks to Buy Before Q1 2026

By Thomas Hughes. Publication Date: 12/9/2025. 

Newspaper headline on a desk highlights rising interest in high short-interest stocks ahead of Q1 2026.

What You Need to Know

  • Many quality stocks with robust outlooks have been heavily shorted in the back half of 2025, setting them up to rebound in 2026.
  • AI demand, either for infrastructure or services, is a dominant theme.
  • This article examines five of the most-shorted stocks with potential to be squeezed and what might trigger the action. 

JPMorgan Chase (NYSE: JPM) will kick off peak fiscal Q4 2025 reporting on Jan. 13, 2026, so there isn’t much time left to position for the season. The takeaway in early December is that many stocks with solid outlooks have been heavily shorted, leaving prices depressed and setting them up for potential rebounds next year.

Now is the time to start building exposure. This article examines five of the highest short-interest stocks on Wall Street, their earnings outlooks, and what might trigger a short squeeze in their share prices.

Hims & Hers Health Could Double in Price

Is President Trump’s latest deal being censored? (Ad)

The “Mandatory Payout” Law – 26 U.S. Code § 857

There is a special class of company legally required to pay out 90% of profits… They’re forced by 26 U.S. Code § 857. And right now, a specific group of these companies is perfectly positioned to profit from a new decision by President Trump. A former Presidential Advisor explains how to get in on these “Mandatory Payout” stocks in his latest briefing…Get the name and ticker of his #1 “Mandatory Payout” stock to buy now, FREE

Hims & Hers Health (NYSE: HIMS) came under pressure in early 2025 for understandable reasons: shifts in the GLP-1 market and service execution issues weighed on sentiment. By late 2025, however, the impact of those GLP-1 headwinds appears to have been temporary, and efforts to expand services and market penetration are gaining traction. The outlook for fiscal Q4 (FQ4) is for growth to slow into the high-20% range, but the bar is low and outperformance is likely. With short interest at 30%, a squeeze is quite possible.

Additionally, the company has been in talks with Novo Nordisk (NYSE: NVO) regarding the sale of the GLP-1 treatment Wegovy, and a share buyback authorization was recently approved. Management plans to repurchase $250 million of stock—about 3% of market cap—underscoring financial flexibility and confidence in the growth outlook.

Analysts have been raising price targets and issuing upgrades in early December, with the consensus implying roughly a 15% rebound. Positive results could push the stock toward consensus targets, above key moving averages, and back toward the highs set earlier in the year.

HIMS chart shows the uptrend holding support as momentum stabilizes for a potential rebound.

Applied Digital: Outperforms, Capacity Is Sold Out

Applied Digital (NASDAQ: APLD) appears to be in the early stages of a short-covering rally. Recent results from Applied Digital and GPU-maker NVIDIA (NASDAQ: NVDA) indicate that AI capacity is sold out and demand remains strong. The takeaway is that APLD’s optimistic forecasts are being validated and its longer-term outlook is improving. The company is on track to complete its second campus and move toward a third, which could lift revenue potential by roughly 50% once built out.

Short interest in APLD was north of 30% in late November and has likely come down since as the share price began to rally in early December, supported by improving analyst sentiment.

Among 13 analysts covering the name, the consensus rating is a Moderate Buy, and price targets have moved higher. The consensus still trails the market but has climbed materially over the past year; the high end of the range points to roughly 30% upside and a potential new all-time high.

APLD chart shows a rebound from support with short-covering beginning to fuel upside momentum.

SoundHound: 30% Short Interest and an Inflection Point Ahead

SoundHound (NASDAQ: SOUN) carried roughly 30% short interest as of late November. While some worry that earlier hype inflated expectations, underlying deal activity tells a different story.

The company is expanding its voice-activated AI services into new verticals and deepening penetration with existing clients, building momentum over recent quarters. Heading into 2026, SoundHound is approaching an inflection point where profitability appears achievable. The FQ4 release will give management a chance to clarify the path forward, and the update could be well received by the market.

The consensus expects revenue growth to slow but remain at a torrid pace of nearly 60%.

SOUN chart shows firm support, though near-term concerns continue to outweigh long-term strengths.

Super Micro Computer: Market Waiting for Proof

Super Micro Computer (NASDAQ: SMCI) has faced a string of challenges, including a recent weak report, leaving the market in a cautious, wait-and-see stance.

SMCI reported fiscal 2026 Q1 earnings on Nov. 4. Its guidance for FQ2 was about 2,500 basis points better than expectations, a signal that should prompt short-covering once the market fully digests it.

The likely catalyst will be stronger-than-expected AI and GPU demand showing up in the server business and guidance, pushing results above consensus and providing clear upside. In the meantime, analysts’ sentiment is coalescing around the consensus estimate, which implies about 35% upside in the stock.

SMCI chart shows shares holding support as investors wait for clearer results before a breakout.

MP Materials’ Market Follow-Through Is Likely Coming

MP Materials (NYSE: MP) saw an early-2025 price surge that signaled longer-term strength. The key question is when the broader market will follow through on that signal—likely in early 2026.

The company benefits from U.S. government support and, unlike many rare-earth hopefuls, is already generating revenue and profit rather than simply promising future production.

Short interest in MP is lower than some names on this list but still meaningful enough to accelerate a move higher when catalysts arrive. Analyst coverage is expanding, the consensus rating is a Moderate Buy, and the forecast implies about 30% upside.

MP chart shows a pullback into a buy zone with support and stabilizing momentum suggesting potential upside.

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO’s, CFO’s, COO’s and other insiders.

This email communication is a paid sponsorship sent on behalf of T3 Live, a third-party advertiser of InsiderTrades.com and MarketBeat. 


Disclosures


If you need help with your newsletter, please feel free to email MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.

Copyright 2006-2025 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, S.D. 57103. USA..

From Our Partners: 5 Stocks That Could Double in 2026 (Click to Opt-In)

Amazon’s January 1 move could change everything

InvestorPlace
InvestorPlace logo

Editor’s Note: We’re passing this along because longtime analyst Whitney Tilson is raising a flag about Amazon that most people aren’t seeing.

While the headlines focus on layoffs and regulatory pressure, Tilson believes a very different story is taking shape — tied to a project Jeff Bezos has quietly funded for more than a decade.

We encourage you to get the full details below while there is still time.


Dear Reader,

Something big is about to come out of Amazon – and almost nobody sees it yet.

Yes, the headlines have been brutal: the FTC’s $2.5 billion settlement… a fresh wave of layoffs… politicians lining up to call Amazon a monopoly or a tax cheat.

But while Wall Street is obsessing over these distractions, Amazon has quietly been preparing for the most important business shift in its history – a shift I believe will be revealed as early as on January 1.

Here’s what almost no one realizes:

For fourteen years, Jeff Bezos has been funding a technology most investors don’t even know exists. Bezos hasn’t shared this with the public but now, I believe he’s finally ready to roll his plan out to the masses.

If Bezos succeeds, Amazon won’t just dominate e-commerce or cloud computing. It could take the lead in a new $40 trillion market – one I could see becoming larger than AI, quantum computing, crypto, EVs, and robotics combined.

I’ve been here before.

Back in 2012, the media called Netflix “a train wreck.” Analysts mocked its price hikes. Its CEO Reed Hastings was being blasted by customers and investors alike. But I tuned out the noise, went on CNBC, and told everyone who would listen that it was the steal of the decade. Netflix went on to rise more than 15,000%.

What’s happening with Amazon today feels eerily similar.

But what I recommend you do about it may surprise you.

Click here for the full story.

Regards,

Whitney Tilson
Editor, Stansberry Research

This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201.


To ensure that you continue to receive marketing emails from InvestorPlace, please add info@exct.investorplace.com to your address book.

If you no longer want to receive marketing emails from InvestorPlace, please click here to unsubscribe

If you have any questions, please don’t hesitate to contact Customer Service at feedback@investorplace.com or by calling 1-800-219-8592.

© 2025 InvestorPlace, LLC. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201

Terms of Use  |  Privacy Policy  |  Unsubscribe

OFFICIAL REPLAY STREAMING NOW

Dear Investor,

The official replay is now LIVE.

If you missed The America First Investor Summit…

Click here now or press play below.



We shared details on five infrastructure stocks that are poised to 10X or more as America reshores industry…

And it’s already happening…

  • When the Pentagon took a stake in MP Materials, shares soared 50% in a day
     
  • When Trump announced a potential deal with Lithium Americas – shares more than doubled in a single day
     
  • When Great Northern Minerals announced a strategic critical minerals deal – shares soared 200% in a day
     
  • And when Trump announced he’d take a stake in Trilogy Metals – shares exploded 260% in one day!

And one tiny mining stock – trading for under $10 – could be next in line for massive profits.

So if you’ve missed out on these America First winners so far – here’s your second chance.

This is the biggest trend for 2026, and you have a one-time chance to get ahead of it TODAY, with our top 5 America First stocks.

We’ll show you our research, and you’ll see for yourself why billionaire investors like JPMorgan CEO Jamie Dimon, Palantir-backer Peter Thiel, Google CEO Eric Schmidt, along with Elon Musk, Jeff Bezos and many others are going “all in” on America First stocks.

But, shares are already starting to take off.

Today may be your last shot at getting into our top 5 this cheap.

Don’t miss this one.

Click here to watch the replay before it comes offline.

“The Buck Stops Here,”

Behind the Markets is a newsletter offered to the public on a subscription basis. 

While subscribers receive the benefit of Behind the Markets opinions, none of the information contained therein constitutes a recommendation from Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person.

You further understand that we will not advise you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter.

To the extent any of the information contained in Behind the Markets may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. 

Behind the Markets’ past results are not necessarily indicative of future performance. 

Employees of Behind the Markets are subject to certain restrictions in transacting for their own benefit. SPECIFICALLY, EMPLOYEES ARE NOT PERMITTED TO BUY OR SELL ANY SECURITY RECOMMENDED FOR THREE (3) TRADING DAYS FOLLOWING THE ISSUE OF A REPORT OR UPDATE.

Behind the Markets’ Newsletter contains Behind the Markets’ own opinions, and none of the information contained therein constitutes a recommendation by Behind the Markets that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. 

Behind the Markets’ past results are not necessarily indicative of future performance. DO NOT EMAIL Behind the Markets SEEKING PERSONALIZED INVESTMENT ADVICE, WHICH WE CANNOT PROVIDE. 

The Editor’s personal investing goals and risk tolerance may be substantially different from those discussed in the Newsletter and/or circumstances may have changed by the expiration of the three day restricted period, the investment actions taken by the Editor in the accounts the Editor directly or indirectly owns may vary from (and may even be contrary to) the advice and recommendations in the Newsletter.

Investing involves substantial risk. Neither the Editor, the publisher, nor any of their respective affiliates make any guarantee or other promise as to any results that may be obtained from using the Newsletter. While past performance may be analyzed in the Newsletter, past performance should not be considered indicative of future performance. 

No subscriber should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing the prospectus and other public filings of the issuer. 

To the maximum extent permitted by law, the Editor, the publisher and their respective affiliates disclaim any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations in the Newsletter prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses. 

The Newsletter’s commentary, analysis, opinions, advice and recommendations represent the personal and subjective views of the Editor and are subject to change at any time without notice.

The information provided in the Newsletter is obtained from sources which the Editor believes to be reliable. However, the Editor has not independently verified or otherwise investigated all such information. Neither the Editor, the publisher, nor any of their respective affiliates guarantees the accuracy or completeness of any such information. 

The Newsletter is not a solicitation or offer to buy or sell any securities. Further, the Newsletter is in no way intended to be a solicitation for any services offered by Behind the Markets 

Neither the Editor, the publisher, nor any of their respective affiliates are responsible for any errors or omissions in the Newsletter. 

Want to change how you receive these emails?unsubscribe from this listBehind The Markets, LLC. If you have any questions, please contact us at support@behindthemarkets.com, or call at 1-800-851-1965.

Nvidia’s Holy Grail

Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.


The #1 AI Investment
Elon + Nvidia =

Dear Reader,

Do you see this weird looking device?

This is Nvidia’s holy grail.

It contains over 3 terabytes of memory…

80 billion transistors…

And can perform over 60 trillion calculations… per second.
 


This single computer chip goes for $25,000 a pop.

And now…

Elon Musk…

The world’s richest man…

Alongside Nvidia’s CEO Jensen Huang…

Are about to crank it up to 1 million.

At a remote facility in Memphis Tennessee…

You two of them have teamed up with an emerging tech titan…

To build the most advanced AI machine on the planet…

Powered by 1 million of these advanced AI chips.

This Will Unlock the TRUE Power of Artificial Intelligence!

But before you rush out to buy shares of Tesla or Nvidia…

There’s another investment you must consider.

You see, there is ONE company…

That Elon … and Nvidia…

And 98% of the Fortune 500

Are ALL working with…

To prepare for AI 2.0.

Nvidia’s CEO has even said – this company is ESSENTIAL to their ongoing expansion.

>>>See how you can invest in this revolutionary company today.

Elon is expanding this project RAPIDLY…

And just announced a second AI computer

That will need this company in order to build. 

This may be the single greatest way to build wealth from the AI bull market.

But you must take action immediately.

AI is quickly becoming one of the MAIN focuses in Trump’s new administration…

And once Wall Street sees what this AI can really do — it will be too late.

>>>Go here to learn how to invest in Elon new AI venture.

Regards,

James Altucher
Editor, Paradigm Press


Exclusive News

Dell Just Hit a Record in AI Orders—But the Real Test Starts Now

Author: Leo Miller. Article Published: 12/2/2025. 

Dell servers in a data center.

In Brief

  • Dell Technologies experienced a notable increase in value following the company’s latest earnings release.
  • AI server orders broke records, and profitability in this part of the business returned to expected levels.
  • Dell will need to execute strongly on its AI server demand in the long term and improve margins to be a true AI winner.

For many investors, Dell Technologies (NYSE: DELL)has become a divisive artificial intelligence (AI) stock. The company is seeing a large uptick in demand due to AI. Dell just reported its latest financial results, and AI orders hit a record high. If the company meets guidance next quarter, annual sales growth would be between 16% and 17% — a level Dell hasn’t reached in nearly four years.

Still, investors remain uncertain about Dell’s position in the AI ecosystem and whether it can emerge as a long-term winner. Dell’s latest results offer useful context for how the stock should be evaluated going forward.

Dell Raises Guidance as AI Orders Soar

Former Trump Advisor Shares Warning At Mar-A-Lago (Ad)

Trump’s Next Real Estate Deal Could Pay YOU President Trump’s real estate deals have returned as much as 4,800%. That’s enough to turn every $1,000 into $49,000. But his next “real estate deal” is different – and much bigger. It involves federal assets worth an estimated $5.1 trillion. And any American citizen can stake their claim. The mainstream media is largely ignoring this, but a former Trump advisor just went on the record.[GET THE FULL DETAILS HERE]

In Q3 fiscal year 2026 (FY2026), Dell reported revenue of $27.01 billion, an increase of 10.8%. (Note that Dell’s fiscal reporting period is one year ahead of the calendar year.) The result missed Wall Street estimates of $27.26 billion, which implied 11.8% growth. However, adjusted earnings per share (EPS) of $2.59 beat the $2.47 analysts anticipated.

Offsetting the sales miss, Dell raised its full FY2026 guidance for both revenue and adjusted EPS. It now expects sales of $111.7 billion at the midpoint (up from $107 billion previously) and adjusted EPS of $9.92 (up from $9.55). Management said the revenue shortfall was a timing issue rather than a demand problem: many sales expected in Q3 shifted into Q4, and there was enough additional demand next quarter to lift the full-year outlook.

Notably, Dell reported record AI server orders of $12.4 billion, and its AI server backlog rose to $18.4 billion from $11.7 billion in Q2 FY2026 — a clear sign demand exceeded supply. Markets reacted favorably: shares rose 5.8% on Nov. 26, and are up nearly 17% in 2025.

DELL’s AI Demand vs. Profitability: The Market’s Tug-of-War

Dell is clearly playing a significant role in AI, with strong server demand materially improving its outlook. A key question for investors, however, is how profitable those AI sales will be. When Dell builds AI servers it assembles components sourced from other companies.

That includes advanced parts such as NVIDIA (NASDAQ: NVDA) processing chips, high-bandwidth memory (HBM) and NAND memory. With industry concerns about NAND and HBM shortages, component costs can rise and squeeze Dell’s AI server margins.

Dell emphasized that AI server margins returned to its expected “mid-single-digit” range in Q3 after one-time pressures pushed them below target in Q2. That return is encouraging, but mid-single-digit margins remain thin; sustainable margin expansion will be critical for Dell’s long-term profitability.

One path to better margins is broadening the customer mix, a process that appears to be underway. Much current demand comes from large, low-margin neo-cloud customers, while smaller enterprise customers typically provide higher margins. As Dell wins more of those customers, overall AI server margins should improve. Dell says it has over 6,700 unique customers in its pipeline, which supports the idea of a more diverse customer base. Over time the company also hopes to sell more higher-margin hardware, software and services as it becomes more embedded in customers’ AI infrastructure — a credible strategy if it can execute.

Analysts Are Moderately Bullish on DELL

The MarketBeat-tracked consensus price target for Dell sits at just over $161, implying roughly 22% upside. The average price target among analysts who updated estimates after the earnings release is nearly identical.

Analysts see meaningful upside if Dell can demonstrate margin expansion on AI servers. That outcome would likely push price targets higher. Near-term risks include pressure from component pricing and supply constraints, but on balance Dell’s long-term risk-reward profile appears moderately tilted to the upside.

Investors will, however, want to see AI server margins stabilize and then improve over time to continue validating that thesis.

This email message is a sponsored message sent on behalf of Paradigm Press, a third-party advertiser of MarketBeat. Why did I receive this email message?

If you have questions about your account, please contact MarketBeat’s South Dakota based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2025 MarketBeat Media, LLC. All rights reserved.
345 North Reid Place #620, Sioux Falls, S.D. 57103. USA..

From Our Partners: 5 Stocks That Could Double in 2026 (Click to Opt-In)

Trump’s Wealth Reset: Could You Be The First Beneficiary?

Trump’s Reset Can Give Birth To

America’s Greatest Era Yet

A 90-Year cycle may end soon, creating real wealth for early adopters

In 1933, Executive Order 6102 forced everyday Americans to hand over their gold at a fixed rate.

Everyday citizens lost a sizable amount of their hard earned wealth at the stroke of FDR’s pen.

Now, 92 years later, President Trump has focused his energy on making things right.

His next move has the power to trigger a financial reset that could shift trillions of dollars into the hands of the people.

A provision buried in the U.S. Code Title 31, Section 5117 allows the U.S. Treasury to revalue America’s gold reserves from an outdated $42 per ounce to today’s market price. 

That’s a 72x increase!

If activated, it could

  • Reinforce America’s financial dominance
  • Reignite trust in value-backed money, making the dollar valuable again
  • Spark a modern day gold rush once the public understand their choices

And the best part…

Over 60 Million Americans are eligible to become a first wave benefactor in Trump’s Gold Reset. 

However, only those who download a copy of our 2026 Wealth Protection Guide will know the simple steps needed to take part in this historic wealth reset. 

Claim Your FREE Guide Now and discover how to position yourself for this golden opportunity.

Request Your FREE WEALTH PROTECTION GUIDE Today!

CLICK HERE TO GET FREE GUIDE 






Special Report

Salesforce Stock Is Coiled Like a Spring and Ready to Rebound

Written by Thomas Hughes. Article Posted: 12/5/2025. 

Salesforce logo framed by a digital spiral over rising stock chart signals momentum from accelerating AI-driven growth.

Article Highlights

  • Salesforce’s Q3 results affirm that its AI strategy is sound and provides incentives for businesses to accelerate AI adoption.
  • Strong cash flow continues to grow in Q3, supporting a robust capital return outlook.
  • Market dynamics suggest a robust rebound lies ahead and may begin before the year’s end.

An examination of Salesforce’s (NYSE: CRM) stock price chart reveals a market coiled up like a spring.

On one hand, its blue-chip, tech-growth business is healthy and commands broad-based market support.

Elon’s Terrifying Warning Forces Trump To Take Action (Ad)

For the everyday American who’s worked hard to build their nest egg, Trump preserved a IRS loophole that allows you to protect your retirement savings before billions in American wealth are lost. 

Download Your Free 2026 Wealth Protection Guide and execute the simple steps to protect your future.GET THE FREE GUIDE

On the other hand, concerns about its AI strategyand growth outlook have compressed price action. The chart shows solid support at the bottom of a range in December 2025, along with signs of underlying market strength.

The two signals of most interest are the divergences in stochastic and MACD on the weekly price action chart. Divergences such as these—when price action hits a new low but the indicators do not follow—suggest that bears have lost control and bulls are now in charge.

At the same time, these indicators are poised to generate strong bullish signals, and early pre-market action following the Q3 release has confirmed that setup. The question is whether the broader market will follow through — the Q3 results and guidance update suggest it will.

CRM stock chart showing bullish divergence as the stock price hits 12-month low but stochastic and MACD do not follow.

Q3 Earnings Reflect Accelerating Adoption of AI Applications

Salesforce’s Q3 results and guidance update are significant for several reasons: their strength and their impact on adoption. Adoption is crucial for AI applications globally, and these results not only show accelerating adoption at Salesforce but are likely to further accelerate it.

Revenue met expectations at $10.28 billion, up 8.7% year-over-year (YOY), while margins expanded significantly, driven by AI’s impact on Salesforce’s business and operations. Salesforce is becoming a poster child for how AI can improve profitability.

Internal metrics are also strong. The core Subscription and Support business grew 10%, driven by AI adoption and increased agent utilization. Agentforce and Data 360 annual recurring revenue rose 114%, with Agentforce itself up 330%, driven by new and existing clients. The client mix is another signal of momentum: 50% of Agentforce deals came from existing clients expanding their usage.

The remaining performance obligation (RPO) also points to accelerating business in upcoming quarters, having risen 12% compared with the 9% revenue gain.

Margins and earnings are accelerating as well, supporting the company’s long-term profitability goals. Key takeaways from Q3: operating cash flow grew 17% versus an 8.7% top-line advance, and free cash flow equaled about 95% of operating cash flow and was up 22% YOY.

Looking ahead, the company expects these strengths to continue, issuing better-than-expected guidance with EPS targets above MarketBeat’s reported consensus. Analysts are targeting $11.38 in adjusted full-year earnings; the company expects closer to $11.75 and is likely being conservative in its estimates.

Salesforce Analysts Signal a Bullish Shift in Sentiment Trends

Analysts never turned outright bearish on the stock, but a series of price target reductions was enough to cap gains and pressure the market in 2025.

Post-release activity includes numerous reaffirmed or reiterated ratings and price targets, signaling that the sentiment downdraft may be over.

As of early December, the consensus among 39 analysts is a Moderate Buy with a forecast for 35% upside. A move to that consensus would push the stock above key moving averages and resistance levels, near the high end of its trading range and within striking distance of a record high.

Institutions have been accumulating CRM stockthroughout 2025, providing solid support and are unlikely to change course soon. The company’s improving outlook, including rising profitability, is generating significant operating and free cash flow.

Free cash flow is a fundamental factor underpinning the stock price outlook because it enables capital returns. The dividend is modest — yielding only 0.7%— but buybacks are more meaningful, reducing the share count by 1.3% for the quarter and year to date, and are expected to continue into the current quarter and next year.

This message is a sponsored message for American Hartford Gold, a third-party advertiser of MarketBeat. Why was I sent this email message?

If you need assistance with your subscription, please don’t hesitate to email our U.S. based support team at contact@marketbeat.com.

If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.

© 2006-2025 MarketBeat Media, LLC. 
345 N Reid Pl. #620, Sioux Falls, South Dakota 57103-7078. USA..

From Our Partners: 5 Stocks That Could Double in 2026 (Click to Opt-In)

Walmart’s NASDAQ Switch Could Change Everything for WMT Stock

  Read Online

Walmart’s NASDAQ Switch Could Change Everything for WMT Stock 

Walmart’s move to NASDAQ — the largest exchange transfer in history — is a bid to recast the retailer as an AI-driven tech innovator and attract new investors. The stock remains in a long-term uptrend, but technicals suggest a possible short-term cooling-off. 

Elon’s Terrifying Warning Forces Trump To Take Action (From American Hartford Gold)

A Walmart checkout lane with a blue reusable Walmart bag filled with groceries, sitting beside the payment terminal.

Summary

  • Walmart begins trading on NASDAQ, marking the largest stock exchange transfer in history with a $905 billion market cap.
  • The move signals Walmart’s strategic push to be viewed as a tech-forward, AI-first retail innovator rather than just a big-box chain.
  • WMT stock continues its long-term uptrend, though technical indicators suggest a short-term cooling period could follow.

There’s something different about Walmart Inc. (NASDAQ: WMT) this holiday season, and it has nothing to do with the health of the consumer. On Dec. 9, the company began publicly trading on the NASDAQ exchange. But what does this mean for an investor?

At a surface level, nothing’s changed. WMT stock is up slightly since the announcement, but that’s part of a trend that’s been in place for five years, and in fairness, you could go back 10 years or more. In fact, since it first began trading on the NYSE, the stock climbed over 536,000%.

However, this move isn’t about where Walmart has been but more about where it’s going. Over the past decade, Walmart has made strategic investments in robotics, artificial intelligence, and machine learning. The move to the NASDAQ is the company’s way of attracting investors who might not view WMT as a technology stock.


How to target 4X returns (Ad)

Wall Street has convinced millions that options are the only path to big gains — all while quietly stacking the deck with decay, timing pressure, and built-in failure triggers. Jeffry Turnmire says there’s a better way: a little-known class of “Supercharged Tickers” that trade like normal stocks but can deliver option-like returns without the hidden time bombs that drain most traders’ accounts. He’s now revealing exactly what they are, how they work, and the #1 ticker he’s watching right now.

Click here to see how Supercharged Tickers can amplify returns without trading options


Here’s Why Investors Should Expect More of the Same

Walmart has been one of the best retail stocksinvestors could have owned. It became part of the Dow 30 in 1997 and has been there ever since. By the way, that’s not going to change. That means that Walmart stock will still be a bellwether for the consumer and the economy at large.

Over the last few years, in the face of consumers stressed by sticky inflation and, more recently, uncertain tariff policies, the company has managed to deliver value to consumers at all price levels.

It’s also rewarded shareholders with stock buybacks, a stock split, and a safe dividend that has a modest yield and has increased for 53 consecutive years. On its last day as an NYSE stock, WMT stock had a market cap of over $905 billion. That makes this the largest stock exchange transfer in history.

Will Walmart’s Perception Shape Investors’ Reality

So why the switch? Walmart wants investors to view the company as a tech-focused, AI-first company, more so than the world’s largest legacy retail chain. The NASDAQ is known as the technology index. It’s the home of all the Magnificent Seven stocks, and it’s the place for companies that want to redefine their industries based on technological innovation.

It’s fair to say that Walmart has done that. Some may argue that Walmart is following the lead of Amazon.com Inc. (NASDAQ: AMZN). If so, the company has closed the gap considerably. Chief financial officer (CFO) John David Rainey remarked that Walmart “is setting a new standard for omnichannel retail by integrating automation and AI to build smarter, faster, and more connected experiences for customers, while enabling our associates to deliver even greater value at scale.”


5 Best Stocks Under $5 to Buy Now (Ad)

5 Best Cheap Stocks Under $5! 

Ready to discover hidden gems in the stock market? 📈 Download our free report featuring 5 top stocks trading under $5 with massive growth potential.

Perfect for value-driven investors looking to uncover low-priced winners. Don’t miss out!


Should You Buy WMT Stock or Sell the News?

Walmart’s valuation certainly supports its inclusion in the NASDAQ. As of Dec. 10, the company’s price-to-earnings (P/E) ratio was 40.3x. That’s higher than the aforementioned AMZN stock. It’s also higher than Microsoft Corp. (NASDAQ: MSFT). In fact, it’s only slightly lower than NVIDIA Corp. (NASDAQ: NVDA), which has a P/E ratio around 45x.

The chart looks extended, but not particularly vulnerable to a deep pullback. Since the company’s earnings report in November, the stock is at new highs that are being supported by rising volume.

The slope of the stock’s 20- and 50-day simple moving averages (SMAs) is decisively upward. This usually indicates a strong intermediate uptrend rather than a blow-off top.

That said, the relative strength indicator is over 70, and the MACD is starting to look tired. It’s entirely possible that a cooling-off period is in order. But that would likely align with the 20-day SMA as primary support and the 50-day SMA as secondary support. That would fit the pattern of prior consolidations on the chart.

Walmart surges to new highs, holding above primary support with secondary support lower on the chart.

Read this article online ›

Featured Stories

Update your email preferences or unsubscribe here

345 N Reid Place #620
Sioux Falls, SD 57103, United States of AmericaTerms of Service 

(Nasdaq: CVKD) Jumps Green Out Of Today’s Bell (Huge Acquisition News Circulates)

*Sponsored

(Nasdaq: CVKD) Jumps Green Out Of Today’s Bell (Huge Acquisition News Circulates)

*Click Here To Get Our Alerts Faster Via SMS*

December 12th

Dear Reader,

Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is making early green moves this Friday while holding the top spot on my watchlist.

Could it be because of this week’s game-changing acquisition announcement?

If you haven’t yet, check it out:

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

From the article:

“With the acquisition of VLX-1005, Cadrenal continues to advance novel therapeutics to treat or prevent thrombosis in high-risk patients,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “HIT remains a dangerous condition without a therapy that addresses its immune-driven biology. The emerging data from VLX-1005 suggest meaningful potential to improve patient outcomes while maintaining favorable tolerability. We believe this is a compelling strategic addition to our pipeline, with the market size for HIT reaching $1Bn in the US and EU.”

Don’t forget. CVKD has a very low float.

With approx. 1.54Mn shares in its float, it’s critical to watch for heightened volatility potential.

Take a moment to review my initial (Nasdaq: CVKD) report below and consider this profile for your radar.

—–

A specialized cardiovascular drug developer has just announced an agreement to acquire a late-stage, first-in-class asset targeting a key enzyme pathway implicated in serious clotting complications linked to common hospital therapies.

This 12-lipoxygenase program, including the VLX-1005 candidate and related assets, is intended to complement the company’s existing focus on high-need anticoagulation settings, where current options often leave patients at meaningful risk.

With the deal structured around future clinical and regulatory milestones, leadership appears intent on carefully deploying capital while advancing a differentiated approach to complex, immune-driven thrombotic disease.

Now, mix in a low float of fewer than 2Mn shares and a pair of analyst targets suggesting SIGNIFICANT upside potential, and there’s no doubt why this Nasdaq profile just rocketed up my watchlist.

Drop what you’re doing and consider this under-the-radar idea for your radar:

*Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)*

Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease.

Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy.

Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.

And based on several potential breakout catalysts, (Nasdaq: CVKD) has found its way to the top of my watchlist. Check them out:

#1. A Mind-Blowing December Acquisition Positions CVKD For Disruption Of A $40Bn Global Anticoagulation Market.

#2. A Low Float Could Create An Environment Of Heightened Volatility Potential.

#3. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.

#4. Another Analyst Reiterates A $30 Target For CVKD.

#5. A Major Acquisition Has Game-Changing Potential For Cadrenal’s Pipeline.

But more on those in a second…

Company Breakdown: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an investigational anticoagulant designed as a superior and safer Vitamin K antagonist (VKA) for patients with implanted cardiac devices or rare cardiovascular conditions.

The company strives to improve patient outcomes and reduce major adverse events among these populations, who currently lack any approved chronic anticoagulation options besides warfarin—a medication known for its serious side effects and complex management requirements.

Through its innovative approach, Cadrenal aims to alleviate some of the most significant challenges faced by patients and healthcare providers who rely on warfarin.

Cadrenal’s Phase 3-ready drug candidate, tecarfarin, represents a novel VKA anticoagulant supported by extensive data suggesting its potential to be superior to warfarin, with the possibility of fewer adverse events such as strokes, heart attacks, bleeding, and death.

Tecarfarin has received orphan drug designation for heart failure patients with left ventricular assist devices (LVADs), as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib).

The company is actively pursuing pivotal clinical trials and exploring clinical and commercial partnership opp’s.

Cadrenal also plans to investigate tecarfarin in patients with mechanical heart valves who experience anticoagulation difficulties due to genetic warfarin resistance, polypharmacy, or kidney impairment.

Tecarfarin is metabolized through a different pathway than warfarin, and data indicate that its efficacy remains unaffected by common drug-drug interactions or kidney impairment—challenges that are prevalent among these patient populations.

Phase 2/3 clinical trials have demonstrated that tecarfarin may offer greater stability and increased time in therapeutic range, which is inversely correlated with major adverse events.

As the only new VKA blood thinner in development specifically for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo, seeking to innovate a new anticoagulant that delivers better care to underserved patients.

Tecarfarin’s Metabolic Advantage

Tecarfarin is metabolized via an alternate pathway that is abundant and essentially insaturable, thereby avoiding the bottleneck in the CYP450 pathway where warfarin is metabolized.

VLX-1005 Expands Company’s Portfolio With A Novel Immune-Targeted Approach – 12-LOX Inhibition  

Recent Acquisition – VLX-1005

  • A parenteral (intravenous) 12-Lipoxygenase (12-LOX) inhibitor designed to block key pathways in immune-mediated platelet activation
  • Blocks platelet activation and inhibits thrombus formation
  • Orphan Drug Designation (ODD) for patients with heparin induced thrombocytopenia (HIT)
  • Acquired December 2025

VLX-1005: The only clinical stage 12-LOX inhibitor

VLX-1005 is uniquely positioned to address an underserved indication with a unique mechanism of action (MoA) and expected meaningful impact on thrombotic events beyond that achievable with current anticoagulant therapy.

Clinical Development Pipeline

Grab Sources Here: CVKD Website. CVKD Presentation.

—–

And as I mentioned earlier, (Nasdaq: CVKD) has several potential catalysts to consider immediately. Check them out:

#1. CVKD Potential Catalyst – A Mind-Blowing December Acquisition Positions CVKD For Disruption Of A $40Bn Global Anticoagulation Market.

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

  • Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HIT
  • It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.
  • Orphan Drug and Fast Track designations from the FDA

PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opp. in the $40Bn global anticoagulation market.

VLX-1005 is a novel, potent, selective small-molecule inhibitor of 12-LOX, a key pathway driving immune platelet-mediated inflammation and a contributor to the pathogenesis of HIT. This potentially life-threatening complication can occur in up to 5% of patients exposed to heparin – the most commonly used parenteral anticoagulant – regardless of dose, schedule, or route of administration. HIT antibodies can cause catastrophic and life-threatening arterial and venous thrombosis. Approximately 300,000 patients in the United States are evaluated each year for suspected HIT, and an estimated 56,000 confirmed diagnoses occur each year. Mortality and thromboembolic event (TE) rates remain high despite currently available therapies.

Two Phase 1 studies of VLX-1005 in healthy participants have demonstrated that VLX-1005 was well tolerated, with no deaths, no serious adverse events, and no trend in adverse event reporting with increasing doses. A recent Phase 2 study (VLX-1005-003) evaluated VLX-1005 in individuals with suspected HIT, and interim results demonstrated encouraging reductions in thromboembolic events. These events have become a preferred, clinically meaningful endpoint for regulators, clinicians, and payers, given the rising rates observed in current HIT populations.

VLX-1005 has received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration, as well as orphan drug status from the European Medicines Agency. Second-generation therapeutics targeting 12-LOX are also under development for type 1 diabetes and other immune-mediated and inflammatory diseases.

“We are pleased the advancement of VLX-1005 for the treatment of HIT will continue under the leadership of Cadrenal,” said Matthew Boxer, Co-Founder of Veralox Therapeutics. “The program has found a home in Cadrenal, where it aligns with a shared vision and excitement regarding the promise 12-LOX technology may offer patients.”

“With the acquisition of VLX-1005, Cadrenal continues to advance novel therapeutics to treat or prevent thrombosis in high-risk patients,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “HIT remains a dangerous condition without a therapy that addresses its immune-driven biology. The emerging data from VLX-1005 suggest meaningful potential to improve patient outcomes while maintaining favorable tolerability. We believe this is a compelling strategic addition to our pipeline, with the market size for HIT reaching $1Bn in the US and EU.”

Read the full article here.

—–

#2. CVKD Potential Catalyst – A Low Float Could Create An Environment Of Heightened Volatility Potential.

According to info from the Yahoo Finance website, CKVD has a very low float.

The website reports this profile to have roughly 1.54Mn shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with this volatile potential?

—–

#3. CVKD Potential Catalyst – A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.

Last month, Noble Capital Markets analyst, Robert LeBoyer, reiterated his $45 price target.

From Thursday’s 4:00PM EST closing valuation, that target provides CVKD with a potential upside of 300+%!

Details from the report:

Conclusion. Cadrenal continues to make progress in several tecarfarin indications and its newly acquired portfolio to meet the need for anticoagulants where current drugs are not effective or contraindicated due to safety. We are reiterating our Outperform rating and $45 price target.

—–

#4. CVKD Potential Catalyst – Another Analyst Reiterates A $30 Target For CVKD.

Another analyst, David Bautz of Zacks Small-Cap Research, reiterated their $30 target for CVKD in September.

From its 4:00PM EST close on Thursday, that targets suggests 150+% potential upside for CVKD.

Report highlights:

Cadrenal has now enhanced its pipeline with the acquisition of frunexian and the other Factor XIa inhibitors and we look forward to additional information regarding their development. The shift to focusing on ESKD patients for tecarfarin is important as there is a significant need for effective anticoagulant therapy for those patients and we believe positive results could also serve to de-risk the development of tecarfarin in other indications such as in LVAD patients. Before incorporating frunexian into our model we will wait and see what development path the company decides to pursue with it, thus our valuation remains at $30 per share.

—–

#5. CVKD Potential Catalyst – A Major Acquisition Has Game-Changing Potential For Cadrenal’s Pipeline.

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors

Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings

Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk

PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) — Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors. The acquisition significantly enhances Cadrenal’s pipeline, adding drug candidates that address large and underserved segments of the current $38Bn global anticoagulation market.

eXIthera’s lead asset, frunexian, is a first-in-class, Phase 2-ready intravenous (IV) Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices plays a significant role, such as cardiopulmonary bypass, catheter thrombosis, and other blood-contacting implanted cardiac devices. The acquisition also includes EP-7327, an oral Factor XIa inhibitor, for the prevention and treatment of major thrombotic conditions.

“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “These newly acquired assets will expand Cadrenal’s capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk.”

“This acquisition reinforces Cadrenal’s long-term vision of becoming a category leader in anticoagulation,” added Pham. “With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk.”

Read the full article here.

—–

(Nasdaq: CVKD) Recap – 5 Potential Breakout Catalysts Lead The Way

#1. A Mind-Blowing December Acquisition Positions CVKD For Disruption Of A $40Bn Global Anticoagulation Market.

#2. A Low Float Could Create An Environment Of Heightened Volatility Potential.

#3. A $45 Analyst Target Suggests Triple-Digit Potential Upside From Current Levels.

#4. Another Analyst Reiterates A $30 Target For CVKD.

#5. A Major Acquisition Has Game-Changing Potential For Cadrenal’s Pipeline.

—–

Coverage is now officially underway on Cadrenal Therapeutics, Inc. (Nasdaq: CVKD).

As soon as updates pop up, I’ll get them out to you quickly. Talk soon.

Sincerely,

FierceAnalyst | Jaks Swift

Editorial Writer

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (“FI”) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 12/11/2025 and ending on 12/12/2025 to publicly disseminate information about (CVKD:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid seventy two thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither SWN Media LLC, TD Media LLC and their member own shares of (CVKD:US).

Please see important disclosure information here: https://fierceinvestor.com/disclosure/cvkd-fl5jc/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US

Unsubscribe | Update Profile | Constant Contact Data Notice

It’s time to prepare for a Flash Crash

Chaikin Analytics

Dear Reader,

I know this prediction is as uncomfortable as it is unwelcome…

Especially if you’re hoping to see an end to the swift, brutal market swings that have defined 2025 thus far.

Unfortunately, a century of financial data suggests we’re about to see the exact opposite.

And that millions of investor portfolios could soon be devastated by a wave of sharp, painful Flash Crashes.

In fact, I predict the volatility we’ve suffered in recent weeks is just the opening act of a new, painful era of the U.S. stock market.

One that will be DEFINED by these lightning-fast sell-offs.

That’s why I’ve partnered with some of the most accomplished software developers in this industry to deliver you a brand-new solution…

Designed to detect the slightest bearish tremors in a stock… that could turn into lightning-fast 20%-plus crashes, faster than you imagined possible.

We just released a “lite” version, called the Flash Crash Screener.

And I’m giving you free access to it today, when you sign up to join me next Tuesday, December 16.

I encourage you to type any stock you own – or are simply worried about – into this screener before market close today.

If you’ve made any money in the U.S. stock market this year, I believe what you’ll see for the first time on December 16 will be the deciding factor in whether you’re able to keep it.

To register and unlock your free lite Flash Crash Screener access, click here.

Regards,

Marc Chaikin
Founder, Chaikin Analytics

You are receiving this e-mail because you are a subscriber to Chaikin Analytics content. To unsubscribe from special offers like this one, click here to unsubscribe.

Published by Chaikin Analytics, LLC.

You’re receiving this e-mail at pahovis@aol.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. – 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice.

© 2025 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com.